Dexamethasone for cardiac surgery trial (DECS-II) : rationale and a novel, practice preference-randomized consent design

Paul S. Myles, Jan M. Dieleman, Andrew Forbes, Stephane Heritier, Julian A. Smith

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Background: Numerous studies have investigated high-dose corticosteroids in cardiac surgery, but with mixed results leading to ongoing variations in practice around the world. DECS-II is a study comparing high-dose dexamethasone with placebo in patients undergoing cardiac surgery. Methods: We discuss the rationale for conducting DECS-II, a 2800-patient, pragmatic, multicenter, assessor-blinded, randomized trial in cardiac surgery, and the features of the DECS-II study design (objectives, end points, target population, based on practice preference with post-randomization consent, treatments, patient follow-up and analysis). Conclusions: The DECS-II trial will use a novel, efficient trial design to evaluate whether high-dose dexamethasone has a patient-centered benefit of enhancing recovery and increasing the number of days at home after cardiac surgery.
Original languageEnglish
Pages (from-to)52-57
Number of pages6
JournalAmerican Heart Journal
Volume204
DOIs
Publication statusPublished - Oct 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier, Inc.

Fingerprint

Dive into the research topics of 'Dexamethasone for cardiac surgery trial (DECS-II) : rationale and a novel, practice preference-randomized consent design'. Together they form a unique fingerprint.

Cite this